Table 3

First-line and second-line therapies in patients receiving metformin (as monotherapy or as part of a combination treatment) as a first-line therapy, according to study region

Africa
n=778 (6.6)
Americas
n=1799 (15.2)
South-East Asia
n=3052 (25.8)
Europe
n=3055 (25.8)
Eastern Med.
n=1819 (15.4)
Western
Pacific
n=1334 (11.3)
Overall
n=11 837
First-line therapy with MET
 MET monotherapy678 (87.1)1543 (85.8)1496 (49.0)2509 (82.1)1055 (58.0)1207 (90.5)8488 (71.7)
 MET combination therapy100 (12.9)256 (14.2)1556 (51.0)546 (17.9)764 (42.0)127 (9.5)3349 (28.3)
  MET+SU73 (9.4)135 (7.5)1045 (34.2)297 (9.7)521 (28.6)68 (5.1)2139 (18.1)
  MET+DPP-4i1 (0.1)94 (5.2)123 (4.0)109 (3.6)130 (7.1)32 (2.4)489 (4.1)
  MET+SU+DPP-4i1 (0.1)14 (0.8)97 (3.2)29 (0.9)70 (3.8)6 (0.4)217 (1.8)
  MET+other(s)*25 (3.2)13 (0.7)291 (9.5)111 (3.6)43 (2.4)21 (1.6)504 (4.3)
Second-line therapy with MET724 (93.1)1629 (90.6)2424 (79.4)2547 (83.4)1610 (88.5)1121 (84.0)10 055 (84.9)
 MET monotherapy4 (0.5)5 (0.3)16 (0.5)4 (0.1)5 (0.3)1 (0.1)35 (0.3)
 MET combination therapy720 (92.5)1624 (90.3)2408 (78.9)2543 (83.2)1605 (88.2)1120 (84.0)10 020 (84.6)
  MET+SU452 (58.1)534 (29.7)729 (23.9)478 (15.6)243 (13.4)306 (22.9)2742 (23.2)
  MET+DPP-4i20 (2.6)557 (31.0)486 (15.9)926 (30.3)604 (33.2)547 (41.0)3140 (26.5)
  MET+SU+DPP-4i1 (0.1)62 (3.4)329 (10.8)132 (4.3)369 (20.3)27 (2.0)920 (7.8)
  MET+insulin†67 (8.6)105 (5.8)107 (3.5)269 (8.8)116 (6.4)9 (0.7)673 (5.7)
  MET+other(s)*180 (23.1)366 (20.3)757 (24.8)738 (24.2)273 (15.0)231 (17.3)2545 (21.5)
Second-line therapy without MET54 (6.9)170 (9.4)628 (20.6)508 (16.6)209 (11.5)213 (16.0)1782 (15.1)
 SU monotherapy21 (2.7)23 (1.3)82 (2.7)163 (5.3)27 (1.5)45 (3.4)361 (3.0)
 DPP-4i monotherapy3 (0.4)65 (3.6)130 (4.3)134 (4.4)62 (3.4)88 (6.6)482 (4.1)
 Other monotherapy*2 (0.3)36 (2.0)253 (8.3)91 (3.0)35 (1.9)51 (3.8)468 (4.0)
 Insulin†18 (2.3)24 (1.3)42 (1.4)44 (1.4)17 (0.9)3 (0.2)148 (1.3)
 Other combinations without MET10 (1.3)22 (1.2)121 (4.0)76 (2.5)68 (3.7)26 (1.9)323 (2.7)
  • Data are reported as n (%). Percentages were calculated for all patients with data available; patients with missing data were excluded. Countries were grouped according to the WHO regional classification (Africa: Algeria and South Africa; Americas: Argentina, Brazil, Canada, Colombia, Costa Rica, Mexico and Panama; South-East Asia: India and Indonesia; Europe: Austria, Czech Republic, Denmark, France, Italy, Netherlands, Norway, Poland, Russia, Spain, Sweden and Turkey; Eastern Mediterranean: Bahrain, Egypt, Jordan, Kuwait, Lebanon, Oman, Saudi Arabia, Tunisia and United Arab Emirates; Western Pacific: Australia, Japan, Malaysia, South Korea and Taiwan).

  • *Including α-glucosidase inhibitors, thiazolidinediones, meglitinides, sodium–glucose co-transporter-2 inhibitors and glucagon-like peptide-1 receptor agonists.

  • †May contain other oral treatments.

  • DPP-4i, dipeptidyl peptidase-4 inhibitor; Med, Mediterranean; MET, metformin; SU, sulphonylurea.